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Abstract
Objective. CD4+ T cells are critical mediators of immunity to
Plasmodium spp. infection, but their characteristics during malarial
episodes and immunopathology in naturally infected adults are
poorly defined. Flow cytometric analysis of PBMCs from patients
with either P. falciparum or P. knowlesi malaria revealed a
pronounced population of CD4+ T cells co-expressing very high
levels of CD4 and CD38 we have termed CD4hiCD38hi T cells. We
set out to gain insight into the function of these novel cells.
Methods. CD4+ T cells from 18 patients with P. falciparum or P.
knowlesi malaria were assessed by flow cytometry and sorted into
populations of CD4hiCD38hi or CD4norm T cells. Gene expression in
the sorted populations was assessed by qPCR and NanoString.
Results. CD4hiCD38hi T cells expressed high levels of CD4 mRNA
and canonical type 1 regulatory T-cell (TR1) genes including IL10,
IFNG, LAG3 and HAVCR2 (TIM3), and other genes with relevance
to cell migration and immunomodulation. These cells increased in
proportion to malaria disease severity and were absent after
parasite clearance with antimalarials. Conclusion. In naturally
infected adults with acute malaria, a prominent population of
type 1 regulatory T cells arises that can be defined by high co-
expression of CD4 and CD38 (CD4hiCD38hi) and that correlates with
disease severity in patients with falciparum malaria. This study
provides fundamental insights into T-cell biology, including the
first evidence that CD4 expression is modulated at the mRNA level.
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These findings have important implications for understanding the
balance between immunity and immunopathology during malaria.
Keywords: CD4+ T cells, regulatory T cells, malaria, CD4 co-receptor
modulation, CD38
INTRODUCTION
Malaria remains a significant threat to global
health with 228 million cases and 405 000 deaths
estimated in 20181. The causative agent, the
Plasmodium spp. parasite, has a complex
multistage life cycle that has co-evolved with the
human host. The human immune response to the
parasite is complex and engages innate and
adaptive cellular and humoral immune
components, and the parasite has developed
multiple strategies to avoid the host immune
response in order to persist. Managing the
balance between controlling a rapidly multiplying
and potentially fatal pathogen and avoiding
immunopathology is difficult (reviewed in Coban
et al.2,3). Because of the complexity of this
parasite–host relationship, immune correlates of
protection remain unknown despite many
decades of intensive research, and the
development of an effective vaccine has proved
elusive.
The blood stages of the Plasmodium spp.
parasite life cycle are responsible for the clinical
symptoms of malaria. Animal studies have
demonstrated a critical role for CD4+ T cells in the
control of the blood stage of Plasmodium
infection (reviewed in Kurup et al.4), and
immunisation studies utilising controlled human
malaria infection (CHMI) of malaria-na€ıve human
volunteers have associated protection from
reinfection with CD4+ T-cell responses5,6.
Furthermore, mounting evidence in humans and
animal models suggests that CD4+ T cells perform
a critical cytokine-mediated balancing act in order
to mediate immunity without pathology, in
particular, via production of pro-inflammatory
cytokines including IFN-c and TNF-a, and the
immunosuppressive cytokine IL-10 (reviewed in
Kumar et al.7).
In CHMI studies, we have shown that the
control of the parasite in malaria-na€ıve volunteers
following the infection with P. falciparum-
infected red blood cells (pRBCs) is associated with
the expansion of a population of CD4+ T cells co-
expressing the activation marker CD388. However,
in naturally exposed individuals from Uganda, an
increased frequency of CD38-expressing CD4+ T
cells predicts treatment failure9, and in another
study, CD38+ CD4+ T-cell frequency correlated
positively with HIV viral load, which was further
accentuated in patients co-infected with
malaria10.
Although CD38 expression has primarily been
used as a marker of CD4+ T-cell activation, the
CD38 molecule itself performs a multitude of
functions and is ubiquitously expressed in
different tissues. In broad terms, CD38 has three
known functions in T cells: (1) it is a
multifunctional ectoenzyme with activities that
include catalysis of extracellular nicotinamide
adenine dinucleotide (NAD), thereby regulating
extracellular levels of NAD and modulating
intracellular Ca2+ levels (reviewed in Malavasi
et al.11); (2) it acts as a cellular receptor,
associating with the T-cell receptor (TCR) on lipid
rafts on T cells, and transduces activation signals
by phosphorylating tyrosine residues on CD3, ZAP-
70 and LAT11; and (3) it acts as a ligand, capable
of binding CD31 on endothelial cells and
participating in lymphocyte homing and inducing
signalling through CD31 on CD31-expressing
cells11. These functions have particular relevance
in the case of Plasmodium infection: infected RBCs
have very high levels of NAD12, and lysis of
infected RBC releases NAD into the extracellular
milieu, which acts as an immune ’danger signal’
promoting inflammation and activating immune
cells including granulocytes13. CD38 binding CD31
on macrophages negatively regulates TLR4
signalling in those cells, which is particularly
relevant as the major Plasmodium pathogen-
associated molecular pattern molecules (PAMPs)
of glycosylphosphatidylinositol (GPI) and
haemozoin (bound to fibrinogen) are known to
signal via TLR4 and induce the release of pro-
inflammatory cytokines14,15. Taken together, these
observations suggest that CD38+-expressing CD4+
T cells may play a critical role in
immunomodulation during Plasmodium infection
rather than merely being a marker of ’activated’
cells.
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Herein, to better understand the role of CD38+
CD4+ T cells during malaria and in particular
during acute malaria, we assessed the genotypic
and phenotypic characteristics of the CD38+ CD4+
T-cell population present in the peripheral blood
of adults presenting to health facilities in
Indonesia or Malaysia with acute P. falciparum or
P. knowlesi malaria. Unexpectedly, in most
patients, we observed by flow cytometry a
prominent population of CD4+ T cells co-
expressing high levels of CD4 and CD38
(CD4hiCD38hi). Assessment of mRNA expression in
FACS-sorted CD4hiCD38hi T cells confirmed
increased CD4 gene expression relative to non-
CD4hiCD38hi T cells and a prominent signature of
genes associated with regulatory T-cell function
including LAG3, HAVCR2 (TIM3), IL10, together
with other genes that suggest CD4hiCD38hi cells
serve a specialised immunoinhibitory role during
acute malaria.
RESULTS
CD4hiCD38hi T cells arise during acute
malaria
We previously identified a significant positive
correlation between the frequency of CD4+ T cells
expressing normal levels of CD4 and increased
levels of CD38 (CD4+CD38hi cells) and control of
parasite growth during the first seven days of
primary Plasmodium blood-stage infection in
malaria-na€ıve volunteers, using a controlled
human malaria infection (CHMI) model8. However,
the function and characteristics of CD38-
expressing CD4+ T cells in individuals naturally
exposed to malaria, and during an acute malarial
infection, are unknown. To determine whether a
population of CD4+CD38hi cells is present in
individuals undergoing secondary exposure to
Plasmodium, similar to individuals undergoing
primary exposure8, we performed flow cytometric
assessment of CD38 expression on CD4+ T cells
from PBMCs collected from Malaysian and
Indonesian adults who presented to hospitals with
acute uncomplicated P. falciparum malaria or P.
knowlesi malaria (before the commencement of
drug treatment: acute, day 0) (subject details in
Table 1). In most cases of acute falciparum
malaria or knowlesi malaria, we observed a
distinctive and unexpected population of CD4+ T
cells that co-expressed high levels of CD38 and
CD4, which we have termed CD4hiCD38hi cells
(Figure 1a). In paired patient samples taken in
convalescence, 28 days following the successful
drug treatment, the CD4hiCD38hi population was
no longer present (Figure 1a). These CD4hiCD38hi
T cells appear to be an activated subset of
conventional peripheral TCR-ab CD4+ T cells, since
they express CD3 and TCR-ab, but do not express
markers of NK cells (CD56, NKp46), NKT cells (TCR-
Va24) and cd T cells (TCR-cd) and have lost
expression of CD45RA (Figure 1b).
To investigate the functional relevance of these
cells, we evaluated a second cohort of P.
falciparum-infected Indonesian adults, to correlate
the frequency of CD4hiCD38hi cells with disease
severity (subject details in Table 2). The frequency
of CD4hiCD38hi T cells increased with disease
severity (Figure 1c). While CD4hiCD38hi T-cell
frequency was not significantly increased in
asymptomatic (parasitaemic) individuals (AS)
compared with local healthy (parasite-free)
controls (HC), it was significantly increased in









Number, n 16 6 6 8
Age, years [median (IQR)] 30 (19–50) 28 (21–50) 28 (26–32) 46 (42–46)
Males, n (%) 10 (63%) 6 (100%) 0 (0%) 8 (100%)
Parasitaemia (parasites µL1) [median (IQR)] 9663 (3452–38472) BDL 10580 (5037–127760) 377 (120–2149)
HRP2 (ng mL1)a [median (IQR)] 126 (28–183) BDL 588 (318–1020) NA
Haemoglobin (g dL1) [median (IQR)] 13.2 (11.5–14.6) 13.5 (12.2–14.1) 10.8 (8.2–11.7) 13.5 (12.9–15.2)
Ang-2 (pg mL1) [median (IQR)] 3086 (1847–7195) 1355 (584–1812) 3554 (2022–6891) 4006 (3231–5841)
All values are median (interquartile range) unless otherwise indicated.
BDL, below detection limit; NA, data not available.
a
Samples below detection limit were assigned the value of half the detection limit (0.03 pg mL1).
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patients with uncomplicated malaria (UM;
P = 0.0381), and further increased in patients with
severe malaria (SM; P = 0.0117) (Figure 1c).
Although in parasitaemic patients CD4hiCD38hi
T-cell frequency increased with increasing
parasitaemia or plasma HRP2, a marker for
parasite biomass (both r = 0.54; P = 0.0006), there
was no relationship between CD4hiCD38hi T-cell
Figure 1. CD4hiCD38hi T cells arise during acute malaria. (a) Flow cytometric assessment of CD4 and CD38 co-expression on CD4+ T cells in
PBMCs of patients with either P. falciparum or P. knowlesi malaria. Top panels show analysis of samples collected on initial presentation to clinic
(acute day 0), and lower panels show matched patient samples collected after drug treatment and convalescence (conv’ day 28). The percentage
of CD4+ T cells that are CD4hiCD38hi are shown. (b) Representative gating strategy used to identify CD4hiCD38hi T cells. (c) PBMCs collected
from Plasmodium-negative healthy controls (HC; n = 7), Plasmodium-positive, asymptomatic individuals (AS; n = 6) and patients with acute
uncomplicated P. falciparum malaria (UM; n = 20) or severe P. falciparum malaria (SM; n = 11) were analysed by flow cytometry for cell surface
marker expression. CD4hiCD38hi cells are shown as the percentage of total CD4+ T cells. Box plots show the minimum, maximum, median and
interquartile range for data from all participants. Horizontal lines depict the median with interquartile range. Data were analysed using the
Kruskal–Wallis test followed by post-tests comparing each group with HC.
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frequency and either parasitaemia or plasma
HRP2, when data were stratified by disease
severity (Supplementary figure 1). However, in
SM, CD4hiCD38hi relative counts (cell frequency)
correlated with the endothelial activation marker,
Ang2 (r = 0.56; P = 0.07); this relationship was
further supported in a subset with available
absolute counts (n = 7; r = 0.825; P = 0.045)
(Supplementary figure 2).
CD4 expression in CD4hiCD38hi cells is
modulated at the mRNA level
Upregulation of the CD4 co-receptor on CD4+ T
cells has not been described previously in human
malaria or in experimental mouse malaria. To
confirm that the apparent CD4high population was
not an aberration of the flow cytometric analysis,
we FACS-sorted populations of CD4hiCD38hi cells
and CD4+ T cells expressing normal levels of CD4
and intermediate/low levels of CD38 (CD4norm)
from PBMCs collected from adult patients with
acute uncomplicated P. falciparum malaria (gating
methodology as above, shown in Figure 1b), and
then stimulated the cells for 3 h with PMA/
ionomycin and assessed mRNA expression in the
cells by real-time qPCR (Figure 2a). Expression of
CD4 mRNA was significantly increased in the
CD4hiCD38hi population when compared to the
CD4norm cells in the acutely infected samples, but
not in the convalescent samples (Figure 2b). This
suggests that the increased CD4 expression by
CD4high T cells is programmed into the cells at the
RNA level.
Investigating the relative expression of several
other genes, we observed that IFN-c mRNA was
expressed equally by CD4hiCD38hi and CD4norm T
cells at the acute stage, but at the convalescent
stage the CD4hiCD38hi T cells produced
significantly less IFNG mRNA than the CD4norm
cells. This pattern of reduced expression of IFNG
mRNA in the convalescent samples mirrors our
previously published observations for
CD4+CD38high cells from healthy volunteers
(malaria-na€ıve Australian volunteers) and for
CD4+CD38high cells from CHMI volunteers at day 7
of infection8. Unlike IFNG, CD4hiCD38hi cells
produced significantly more IL10 mRNA at the
acute stage, but this was lost at the convalescent
stage (Figure 2b). Both CD4hiCD38hi and CD4norm
cells expressed low levels of FOXP3 (Figure 2b).
This pattern of co-expression of IFN-c and IL-10
together with an absence of FOXP3 expression has
been observed in CD4+ T cells from children living
in malaria-endemic regions who have suffered
recent malarial episodes16-18 and is associated
with a type 1 regulatory T-cell phenotype (TR1)
(reviewed in Roncarolo et al.19,20). Those studies
reported CD4+ (CD4norm) T cells only and did not
identify CD4hi cell populations.
Given the increased frequency of CD4hiCD38hi T
cells in patients with uncomplicated malaria and
severe malaria, compared with asymptomatic but
parasitaemic individuals and healthy uninfected
controls, we next assessed whether CD4hiCD38hi T
cells recognise Plasmodium antigens. PBMCs
collected from adult patients with acute
uncomplicated P. falciparum malaria were
incubated for 24 h with an extract made from P.
falciparum-parasitised RBCs (pRBCs) or a control
extract made from non-infected RBCs (nRBCs).
Immediately following this in vitro stimulation,





malaria (UM) Severe malaria (SM) P-valuea
Number, n 7 6 20 11
Age, years [median (IQR)] 30 (25–35) 21 (18–25) 33 (25–41) 25 (23–36) 0.0208
Males, number (%) 6 (86) 6 (100) 13 (65) 7 (64)
Parasitaemia(parasites µL1)
[median (IQR)]
0 (0–0) 85 (62–6956) 2048 (374–7113) 176 758 (91 786–508 775) < 0.0001
HRP2 (ng mL1)b 0.03 (0.03–0.03) 0.3 (0.3–3.1) 34 (0.3–109.6) 5691 (3651–12 247) 0.0003
Haemoglobin (g dL1) 12 (11–16) 11 (9.5–13.25) 11 (10–12.75) 9 (8–12) 0.1142
Angiopoietin-2 (pg mL1)
[median (IQR)]
2511 (1940–3465) 3255 (2666–4698) 3181 (2144–3911) 25 025 (5300–42 177) < 0.0001




Samples below the detection limit were assigned the value of half the detection limit (0.03 pg mL1).
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the CD4hiCD38hi and CD4norm cells were sorted by
flow cytometry (as above) and placed into RLT
lysis buffer for mRNA processing without further
stimulation. CD4hiCD38hi cells exposed to pRBC
responded with an increase in IFNG mRNA that
was not observed for CD4norm cells or when the
control extract was used (Figure 2c). IL-10 levels
were elevated in CD4hiCD38hi cells from P.
falciparum patients regardless of antigen
exposure.
CD4hiCD38hi cells express specialised
regulatory T-cell genes
In order to gain a more in-depth insight into the
function and phenotype of CD4hiCD38hi T cells,
we next utilised the NanoStringTM technology
platform to assess the differential mRNA
expression of 130 genes associated with T-cell
function in CD4hiCD38hi and CD4norm cells in acute
malaria. CD4hiCD38hi and CD4norm cells were
Figure 2. Increased CD4 expression in CD4hiCD38hi cells is modulated at the mRNA level. (a) Experimental plan for cell sorting, stimulation and
gene expression analysis. (b) Gene expression assessment by qPCR of FACS-sorted CD4norm (norm) and CD4hiCD38hi (high) T cells from patients
with acute P. falciparum malaria (n = 6, log2-normalised data, paired t-test). (c) P. falciparum antigen-specific responses measured in FACS-sorted
CD4norm (blue squares) and CD4hiCD38hi (red circles) T cells from patients with acute P. falciparum malaria (Pf inf’) or healthy Sabah controls (HC)
by qPCR after 24-h co-incubation with extract made with P. falciparum-infected RBC (pRBC) or normal RBC (nRBC) (n = 3 Pf inf’ and n = 3 HC,
log2-normalised data, paired t-test).
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sorted from PBMCs collected from acutely infected
individuals (Table 1; methodology as above in
Figure 2a) with P. falciparum infection (6 patients
from Papua and 6 from Sabah) or P. knowlesi
infection (6 patients from Sabah).
Of the 130 genes, 78 were reproducibly detected
across the groups and were included in further
analysis (Supplementary table 1). We first assessed
differences between the P. falciparum (n = 12) and
P. knowlesi (n = 6) samples with a principal
component analysis (PCA) using the Genomics
Data Miner (GMine)21, and also by comparing the
fold change in gene expression between the
CD4hiCD38hi and CD4norm cells by ANOVA
(Figure 3a). Since our analysis revealed no
significant differences between the P. falciparum
and P. knowlesi data sets (FDR < 0.05), we
combined those data and performed a PCA
comparing differential gene expression between
CD4hiCD38hi and CD4norm cells, as well as a paired
t-test of CD4hiCD38hi and CD4norm cells from each
subject (n = 18) (Figure 3b). In total, 49 genes
were significantly differentially expressed between
the CD4hiCD38hi and CD4norm cells (FDR < 0.05,
Supplementary table 1 and Figure 3b and c).
Next, we performed a linear discriminant effect
size analysis (LEfSe)22 using GMine to identify
features most likely to explain the differences
between the CD4hiCD38hi and CD4norm
populations (using all 78 detected genes)
(Figure 3d); and a Random Forest analysis to
identify the most relevant features of the cohort
(Figure 3d) (GMine). Both analyses identified
expression of a distinct set of genes associated
with T reg function in the CD4hiCD38hi cells,
including genes strongly associated with TR1
cells19: IL10, LAG3, HAVCR2 (TIM3), PDCD1 (PD1),
IL21, ICOS, MAF and PRF1. Furthermore, another
canonical TR1 cytokine, TGFB1, was very highly
expressed in both the CD4hiCD38hi and the
CD4norm subsets (but not differentially expressed)
(Figure 3c, lower panel).
Insight into the ontogeny of CD4hiCD38hi
cells
We utilised the Ingenuity Pathway Analysis
platform and the data generated in the
NanoString study (above) to predict upstream
regulators of the CD4hiCD38hi cells. Using this
method, the cytokine IL-27 was identified as a
potential inducer of these cells (Figure 4a and b).
To test whether IL-27 could indeed induce the
CD4hiCD38hi cell population in vitro, we cultured
PBMCs from healthy malaria-na€ıve (Brisbane)
volunteers with P. falciparum-parasitised RBC
extract for 14 days +/ recombinant human IL-27.
Cells cultured in the presence of IL-27 displayed
significantly increased co-expression of both CD4
and CD38 by flow cytometry (Figure 4c and d),
and sorted bulk CD4+ T-cell populations from
these cultures displayed enhanced CD4, IFNG, IL10
and LAG3 mRNA expression (Figure 4e).
CD4hiCD38hi cells in mice
We were curious as to why no analogue of the
CD4hiCD38hi cell population has been yet reported
in mice, given the very large number of
immunological studies performed utilising rodent
malaria models including those focused on the
role of CD4+ T cells. Indeed, in our laboratory,
despite many thousands of flow cytometry
analyses conducted using a flow cytometric
method for monitoring Plasmodium infection23,
we have never observed CD4high cells in the blood
of mice during infection. To provide a foundation
for dissecting the role of CD4hiCD38hi cells in
host–pathogen immunity, we revisited our P.
yoelii murine malaria model with a different
approach. To identify CD4+ T cells specifically
responding to infection, we utilised a mouse
model where cells are engineered to express the
fluorescent protein YFP upon the production of
IFN-c24. Using this model, mice were infected with
non-lethal P. yoelii 17XNL-parasitised RBC via
intravenous injection to establish a blood-stage
infection. On days 1, 3, 5, 8 and 11 of infection,
cells were recovered from several organs including
the spleen, blood, bone marrow, liver-draining
lymph nodes (DLNs) and inguinal lymph nodes
(Ing LNs). Using this more-focused approach, IFN-
c-producing CD4+ T cells were evident in the
spleen at day 3 of infection (Figure 5a), but by
day 8, the YFP+ CD4+ T cells were diminished, and
by day 11, the remaining YFP+ CD4+ cells in the
spleen were also CD4high (Figure 5a and b). This
pattern of IFN-c expression coincides with a peak
in plasma IFN-c routinely observed in mouse
models25-27, and in our own experiment in C57BL/
6 mice (Figure 5c) in which plasma IFN-c peaked
around day 3 and IL-10 around day 11. This
timing coincides with the onset of acute
parasitaemia, which can reach very high levels in
the P. yoelii mouse model (Figure 5d). These
CD4high cells were apparent only in the spleen and
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Figure 3. Differential gene expression in CD4hiCD38hi T cells. Differential expression of 130 genes associated with T-cell function was assessed
by NanoString in FACS-sorted CD4norm and CD4hiCD38hi T cells from patients attending a clinic with acute P. falciparum malaria (Sabah (n = 6)
and Papua (n = 6)) or P. knowlesi malaria (Sabah (n = 6)). (a) Differences in fold changes in gene expression from CD4norm to CD4hiCD38hi T cells
were analysed by principal component analysis (PCA) comparing cells from patients with P. falciparum and P. knowlesi malaria (left panel), and
histogram of false discovery rate (FDR) was assessed by ANOVA (right panel). (b) PCA comparing gene expression in CD4norm and CD4hiCD38hi T
cells for combined P. falciparum and P. knowlesi samples and histogram of FDR from a paired t-test (n = 18). (c) Heatmap of 78 genes
reproducibly detected across all samples, showing 49 genes with a FDR < 0.05 in the upper panel (as in 3b above) and the remainder in the
lower panel. (d) Linear discriminant effect size analysis (LEfSe) using fold changes in gene expression from CD4norm to CD4hiCD38hi T cells for all
78 detected genes. (e) Random Forest analysis performed on the same data set (truncated at importance value 3).
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bone marrow, and not in blood, liver DLN or
inguinal LN (Figure 5e). The CD4high cells from the
spleen at day 11 were also CD38high, but the levels
of CD38 were not high enough to make this
population as prominent as observed in the
human studies (Figure 5f). Finally, to assess gene
expression in the CD4high murine cells, CD4high
and CD4norm cells were FACS-sorted from spleens
collected at day 11 of infection and processed
directly for analysis by real-time qPCR without
further stimulation. As in human CD4hiCD38hi
cells, murine CD4hi cells had increased CD4 mRNA
and contained within this population were the
IL10-producing cells with increased LAG3 and an
absence of FOXP3 (Figure 5g). Thus, the
population identified in the P. yoelii murine
model shares core similarities with the
CD4hiCD38hi population in humans.
DISCUSSION
We have identified a population of CD4+ T cells
in the blood of acute malaria patients infected
with P. falciparum or P. knowlesi that co-express
high levels of the CD4 co-receptor and the
ectoenzyme CD38. These CD4hiCD38hi T cells
appear to be an activated subset of conventional
peripheral TCR-ab CD4+ T cells, since they express
CD3 and TCR-ab but do not express markers of
NK cells (CD56, NKp46), NKT cells (TCR-Va24) or
cd T cells (TCR-cd) and have lost expression of
CD45RA. Because of reductions in absolute CD4
T-cell numbers in the blood during acute malaria,
NK cells are relatively more abundant28; hence,
we excluded these based on the expression of
CD56. These CD4hiCD38hi cells also expressed a set
of genes strongly associated with
immunomodulatory function, including IL10,
LAG3 and TIM3 (HAVCR2), and were present in
the peripheral blood of patients in malaria-
endemic areas during acute symptomatic
infection but were absent following the drug
treatment and convalescence.
CD4+ T cells play a critical role in the control of
the blood stage of Plasmodium infection, both in
humans and in animal models (reviewed in Kurup
et al.4,29); however, a clear role also exists for
CD4+ T cells in suppressing immunopathology. The
appearance of IL-10-expressing CD4+ T cells during
Plasmodium infection in humans16-18,30,31 and
mice32,33 has been well documented, and early
reports associated cerebral malaria in children
with high circulating IL-10 levels34-36: one study
found IFN-c/IL-10-co-producing cells in children
with severe malaria17.
CD4hiCD38hi cells appear to provide a more
comprehensive set of markers for TR1 regulatory T
cells as they strongly express canonical TR1 genes
including IL10, IFNG, TGFB1, LAG3, TIM3, IL21,
ICOS, PD1 (PDCD1), MAF, and PRF1 and do not
express FOXP3 (reviewed in Roncarolo et al.19,20).
CD4hiCD38hi cells strongly express CXCL8 (IL-8),
which is a pro-inflammatory cytokine not
previously associated with TR1 cells but shown to
be produced by human FOXP3+ T regs37 and
upregulated by CD4+ T cells very early during
primary Plasmodium infection38. Our cell
population is also distinct from the CD38-
expressing CD4+ T-cell subset identified previously
as a hypoproliferative IL-13-secreting CD4+ T-cell
subset that retained expression of na€ıve cell
surface markers following the TCR stimulation and
secreted IL-13, and IFN-c and TNF39. Note that the
CD4hiCD38hi population described in our study
may or may not be a homogeneous population.
Our pathway analysis (Figure 4) suggested IL-27
as an upstream regulator of the CD4hiCD38hi
phenotype. In vitro studies with mice have
identified IL-27 as an inducer of IL-10 production
in CD4+ T cells40,41 and confirmed a role for IL-27
receptor signalling41, and similar observations
were made with in vitro cultures of human cells42.
In the context of experimental rodent malaria, IL-
27 (acting via the IL-27 receptor) was shown to
induce the generation of IL-10-expressing CD4+ T
cells that were critical to limit
immunopathology32,43. It remains possible that
other cytokines may also induce the CD4hiCD38hi
phenotype; indeed, our pathway analysis
(Figure 4) also identified IL-12 and IL-21 as
potential upstream regulators and others have
shown that IL-6 and TGF-b could induce IL-10
production by CD4+ T cells in mice41. The
mechanisms of CD4hiCD38hi cell generation in vivo
remain to be elucidated, but we think it likely
that IL-27 levels in vivo are likely to be higher
around areas of antigen presentation and more
likely to affect cells responding to antigen. This
may explain the fairly uniform upregulation of
CD4 and CD38 we observed in our in vitro
cultures. Possibly adding support to the notion
that IL-27 is driving the CD4hiCD38hi phenotype in
our patients with acute malaria is a recent paper
by Oterdal et al. who found that IL-27 levels are
elevated in the plasma of adults living in malaria-
endemic areas with acute falciparum malaria44.
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A striking feature of the CD4hiCD38hi cell is its
very high expression of the CD4 co-receptor. The
canonical role of the CD4 co-receptor is to bind a
region on the MHC-II molecule and restrict
signalling through the CD4+ T-cell receptor to
antigens bound only on MHC-II molecules45.
However, the CD4 co-receptor serves multiple
other roles including acting as a receptor for the
chemotactic cytokine IL-1646, and facilitating
adhesion to cells expressing MHC-II independently
of TCR engagement (reviewed in Glatzova et al.47).
The latter is particularly relevant in malaria as
MHC-II expression is dramatically increased on
murine brain microvascular endothelium during
experimental cerebral malaria48, and on human
endothelium in response to IFN-c49.
Figure 4. Ontogeny of CD4hiCD38hi T cells. (a) Predicted upstream regulators of the CD4hiCD38hi cell type identified by Ingenuity Pathway
Analysis (IPA) of fold changes in gene expression from CD4norm to CD4hiCD38hi T cells for the 49 genes identified above with a FDR < 0.05
(truncated at Z-score = 2); and (b) plot of predicted relationships (IPA). (c) Representative FACS plots from one volunteer and (d) differential
expression of CD4 and CD38 on CD4+ T cells assessed by FACS in PBMCs from healthy volunteers (Brisbane) cultured for 2 weeks with pRBC
extract in media containing IL-2 (media) or IL-2 supplemented with IL-27 (+IL-27) (n = 4, paired t-test). (e) Gene expression assessment by qPCR
of FACS-sorted CD4+ T cells from PBMCs cultured as above (n = 4, log2-normalised data, paired t-test).
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Figure 5. Identification of CD4hi cells in the mouse. (a) Kinetic analysis of CD4 and IFN-c expression by FACS in CD4+ T cells in the spleens of
mice (GREAT IFN-c reporter mice) infected with P. yoelii 17XNL. The percentage of CD4+ T cells that are CD4hi and IFN-chi are shown (n = 3 mice
at each timepoint, concatenated FACS data shown). (b) Kinetic analysis of the frequency of CD4hi and IFN-chi in the spleen (n = 3 mice at each
timepoint, one-way ANOVA with Dunnett’s multiple comparison test). (c) IFN-c and IL-10 levels were assessed by cytokine bead array in the
plasma of C57BL/6 mice infected with P. yoelii 17XNL at the timepoints indicated. Left axis indicates IFN-c and right axis IL-10 (n = 10, mean and
SEM shown). (d) Parasitaemia in GREAT IFN-c reporter mice following the infection with P. yoelii 17XNL (n = 3, mean and SEM shown). (e)
Analysis of CD4 and IFN-c expression by FACS on day 11 of infection with P. yoelii 17XNL in CD4+ T cells in the organs indicated in GREAT IFN-
reporter mice. The percentage of CD4+ T cells that are CD4 and IFN-c positive are shown (DLN = draining lymph node, Ing LN = inguinal lymph
node). (f) FACS analysis of CD38 expression in CD4hiIFN-chi cells in GREAT IFN-c reporter mice on day 11 of P. yoelii 17XNL infection. (g)
CD4hiIFN-chi cells (gated as in e above) were FACS-sorted from the spleens of GREAT IFN-c reporter mice on day 11 of infection with P. yoelii
17XNL, and gene expression was assessed by qPCR (n = 3, log2-normalised data, paired t-test, mean with SD shown). Data shown are from three
independent experiments.
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Another vital role of the CD4 co-receptor is to
enhance signalling through the T-cell receptor
during engagement with the peptide–MHC-II
complex50. An analogous effect has been
observed in CD8+ T cells, by us51 and others52,
where the sensitivity of the T-cell receptor was
shown to be modulated by increasing or
decreasing the expression levels of the CD8 co-
receptor. This can increase the range of specificity
of the T cell, thereby allowing a T cell that is
typically restricted to a very specific peptide to be
able to respond in a cognate fashion to a broader
range of targets. In the study reported herein,
CD4hiCD38hi cells responded to parasitised RBC by
strongly expressing IFN-c and IL-10, but did not
respond to uninfected RBC controls, suggesting
that TCR signalling is functioning in these cells
and that they are not exhausted53. However, we
cannot rule out the possibility that some cells
responding to antigen may have started out as
CD4norm prior to the in vitro assay.
Downregulation of the CD4 co-receptor has
been reported in one study in mice54, and several
other studies have demonstrated increased CD4
expression on CD4+ T cells following the very
strong or chronic activation, such as in a mixed
lymphocyte reaction55 or an alloreactive
transplant setting56,57. However, increased CD4
expression in the context of natural host–
pathogen interactions, as shown herein for our
novel CD4hiCD38hi cell population, has not been
previously reported. Importantly, we show that
this increase in CD4 expression is modulated at
the mRNA level, providing the first evidence of
this fundamental insight into T-cell biology. This is
significant because CD4 levels could be transiently
modulated by cycling of the co-receptor between
the cell surface and cytoplasm58; however,
increased CD4 gene expression together with the
required energy expenditure emphasises the level
of commitment to the cell phenotype, suggesting
that increased CD4 expression is important to the
function of these cells.
The unusual characteristics of CD4hiCD38hi cells
are well suited to a specialised T regulatory cell
arising in response to Plasmodium infection.
Firstly, in residents of two distinct malaria-
endemic areas (Sabah and Papua), CD4hiCD38hi
cells were present in relatively large numbers
during acute malaria but were absent in
convalescence following the successful drug
clearance of parasites, and CD4hiCD38hi cells could
recognise Plasmodium-infected RBC in vitro,
suggesting that CD4hiCD38hi cells are responding
directly to Plasmodium infection. Secondly,
CD4hiCD38hi cells express a unique set of genes
with particular relevance to Plasmodium infection,
including those mentioned above and CXCR6
whose ligand (CXCL16) is constitutively expressed
in cerebrospinal fluid59, on endothelial cells in the
brain60 and in the placenta during malaria61, and
may induce migration and localisation of
CD4hiCD38hi to these tissues. CD4 would promote
localisation to areas of increased MHC-II
expression during infection, and CD38 is a ligand
for CD31 (platelet endothelial cell adhesion
molecule, PECAM-1) whose expression on
endothelial cells is upregulated during malaria62,
which may in turn promote CD4hiCD38hi cell
localisation. Consistent with this, it was notable
that the frequency of CD4hiCD38hi cells in severe
malaria was strongly associated with measures of
endothelial activation. CD38 is also a critical
ectoenzyme catalysing extracellular nicotinamide
adenine dinucleotide (NAD), thereby regulating
extracellular levels of NAD released by lysis of
infected RBC12, reducing levels of pro-
inflammatory NAD13 and providing the substrate
ADPR that is further catalysed to generate the
strongly immune-inhibiting molecule adenosine63.
Another role for CD38 is to bind CD31 on
macrophages and inhibit TLR4 signalling, which is
relevant since the major Plasmodium PAMPs of
glycosylphosphatidylinositol (GPI) and haemozoin
(bound to fibrinogen) are known to signal via
TLR4 and induce the release of pro-inflammatory
cytokines14,15.
Taken together, our data suggest that
CD4hiCD38hi cells are a specialised TR1 cell that
arise during acute infection. We propose a role in
limiting immunopathology. In our study,
CD4hiCD38hi cells were increased in proportion to
malaria disease severity (Figure 1c), and there are
phenotypic analogies between the CD4hiCD38hi T
cells identified herein and IL-10-expressing CD4+ T
cells that were shown to limit immunopathology
in a rodent malaria model32. Whether these cells
also inhibit parasite clearance is not known.
Studies in rodents have shown that blocking T
regulatory cell function can enhance parasite
clearance33,64, and Jagannathan et al. found that
the CD4+ T cells co-expressing IFN-c and IL-10 may
associate with an increased risk of future malaria
in children17. In a previous study, we found that
control of the parasite following the infection of
malaria-na€ıve volunteers with P. falciparum-
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infected RBC was associated with an increased
frequency of CD4+ T cells co-expressing CD38, but
these did not have increased expression of CD4,
were poor producers of IFN-c8 and appeared to
be analogous to mouse CD4 T cells activated
in vitro65 and markedly different from those we
describe herein during clinical disease. Whether
the CD38-expressing CD4+ T cells associated with
treatment failure in clinical malaria in Uganda
had increased expression of CD4 was not
reported. While there was no relationship
between CD4hiCD38hi cells and parasite biomass
evident in the current study, parasite clearance
could not be assessed, and the role of this cell
population in parasite clearance requires
prospective study.
In conclusion, we describe herein a population
of CD4+ T cells expressing high levels of CD4 and
CD38 (CD4hiCD38hi cells) in adult patients acutely
infected with either P. falciparum or P. knowlesi.
Assessment of differential mRNA expression of
130 genes associated with T-cell function revealed
that these CD4hiCD38hi cells had a TR1 phenotype,
with high expression of LAG3, IL10, TIM3 and
numerous other genes associated with modulatory
activity. We further provide the first naturally
occurring example of increased CD4 expression on
CD4+ T cells, and the first evidence that changes
in CD4 co-receptor expression levels are
modulated at the mRNA level. These findings give
new insight into T-cell biology and provide a
starting point for future studies that aim to




In Sabah, an area of low malaria transmission, patients
were enrolled from a tertiary referral centre (Queen
Elizabeth Hospital 1, Kota Kinabalu)66,67 and two district
hospitals (Kudat and Kota Marudu) as part of concurrent
prospective clinical studies68. During the sample collection
period, the region was co-endemic for P falciparum, P. vivax
and the zoonotic parasite P. knowlesi69,66. Criteria for
enrolment included a blood film that was positive by
microscopy for any Plasmodium species, fever or history of
fever in the last 48 h, no major concurrent illness or
comorbidity, and no prior antimalarial therapy in the
preceding 24 h. Patients were excluded if pregnant or
lactating. Hospitalisation was mandatory in all patients with
malaria in Sabah. All patients with malaria were treated
according to the local guidelines. Uninfected participants
were visitors or relatives of patients with malaria, with no
fever or history of fever in the preceding 14 days and with
a blood film negative for malaria parasites. Heparinised
venous blood samples were collected at presentation, and
follow-up samples were collected 28 days post-treatment.
Peripheral blood mononuclear cells (PBMCs) were isolated
and cryopreserved until analysis.
In a lowland region of Papua with perennial, unstable
transmission of P. falciparum, P. vivax and P. malariae,
patients were enrolled with malaria attending the Mitra
Masyarakat Hospital in Timika or a regional health clinic.
The following groups of participants were enrolled
following the informed consent, and patients with acute
uncomplicated falciparum malaria (UM) presenting with P.
falciparum monoinfection by microscopy, fever or history of
fever in the preceding 48 h and no alternative cause were
identified (n = 20)70–72: patients with P. falciparum
parasitaemia and ≥ 1 modified WHO criteria of severe
malaria (SM), acute renal failure (creatinine
> 265 µmol L1), or hyperbilirubinaemia with renal
impairment (creatinine > 130 µmol L1) and/or parasitaemia
of > 100 000 parasites lL1, or blackwater fever, or
hyperparasitaemia (> 10% parasitised red cells), or cerebral
malaria (Glasgow coma score < 11), or hypoglycaemia72. In
the SM cohort (n = 11), 3 patients (27%) had cerebral
malaria, 3 patients (27%) had hyperparasitaemia, 5 patients
(45%) had renal failure, 4 patients (36%) had
hyperbilirubinaemia, and 7 patients (64%) had more than
one WHO criterion for severe disease. Asymptomatic
malaria-exposed adults, resident in Timika district for at
least two years, with no fever or symptoms of malaria
within the preceding two weeks were enrolled as controls.
Those without parasitaemia were grouped as healthy
controls (n = 7) and those with asymptomatic parasitaemia
as asymptomatic controls (n = 6). Peripheral blood
mononuclear cells (PBMCs) were isolated from heparinised
venous blood samples and cryopreserved until analysis.
Study approval
The human studies were approved by the ethics committees
of the Malaysian Ministry of Health, the Indonesian
National Institute of Health Research and Development, the
NT Department of Health and Menzies School of Health
Research and QIMR Berghofer Medical Research Institute.
Written informed consent was obtained from all
participants.
Plasma biomarkers
Total body parasite biomass was quantified by detecting
plasma concentration of P. falciparum Histidine Rich
Protein 2 (PfHRP2) using ELISA as described73. Plasma Ang-
2 was measured as a biomarker of endothelial activation
by ELISA (Quantikine, R&D Systems) as previously
described74.
Flow cytometry
PBMCs isolated from adult patients with P. falciparum or P.
knowlesi malaria in Papua or Sabah were cryopreserved and
kept in liquid N2. Frozen samples were thawed in 10
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volumes of complete media (RPMI 1640 containing phenol
red supplemented with 10% FCS and 50 mg L1
gentamicin; Sigma-Aldrich). All antibodies were titrated
before experimental use with PBMCs from healthy
volunteers to determine the optimal staining concentration.
Cells were stained with 50 lL of FACS staining buffer (PBS
supplemented with 0.5% FCS and 2 mM EDTA) containing
combinations of anti-human antibodies as detailed in the
text including the following: CD3-AF700 (BioLegend, clone
OKT3), CD4-BV510 (BioLegend, clone OKT4), CD8-APC-H7
(BD Biosciences, clone SK1), CD38-PerCP/Cyanine5.5
(BioLegend, clone HB-7), TCR-a/b-PE/Cy5 (BioLegend, clone
IP26), CD56-PE-Cy7 (BD Biosciences, clone B159), TCR-c/d-AF-
647 (BioLegend, clone B1), TCR-Va24-Ja18-FITC (BioLegend,
clone 6B11), CD335-BV421 (BioLegend, clone 9E2), CD45RA-
BV-606 (BioLegend, clone HI100) and 1 lL of human Fc
receptor blocking solution (Human TruStain FcX,
BioLegend) for 30 min at room temperature. Cells were
washed and resuspended in FACS staining buffer containing
propidium iodide (Thermo Fisher Scientific) before
acquisition or sorting. In some experiments (e.g. data
shown in Figure 1c), 400 000 PBMCs in PBS/2% FCS were
stained with anti-CD3-FITC (HIT3a), CD4-PerCP (RPA-T4) and
CD38-APC (HIT2) (all from BD Biosciences) for 30 min on ice.
Cells were washed twice and fixed with 1%
paraformaldehyde (Sigma, Australia) before acquisition.
For flow cytometry experiments with mice, single-cell
suspensions from organs as detailed in the text were
prepared and stained with combinations of anti-mouse
antibodies including the following: CD3-PE/Cy5 (BioLegend,
clone 145-2C11), CD3-V450 (BD Biosciences, clone 500A2),
CD4-PE (BioLegend, clone GK1.5), CD4BV510 (BioLegend,
clone RM4-5), GR-1-PE-Cy7 (BD Biosciences, clone RB6-8C5),
CD11a-AF647 (BioLegend, clone M17/4), CD19-AF700
(BioLegend, clone 6D5), CD8-APC-Cy7 (BioLegend, clone 53-
6.7), CD11b-BV711 (BioLegend, clone M1/70), CD11c-BV785
(BioLegend, clone N418) and CD38-PerCp/Cyanine5.5
(BioLegend, clone 90). Propidium iodide or Sytox Red
(Thermo Fisher Scientific) was added to the running buffer.
Data acquisition was performed on a LSRFortessa 4
instrument (BD Biosciences) using Diva software. Cell
sorting was performed using a BD Aria III cell sorter (BD
Biosciences). FlowJo software version 9.9 was used for post-
acquisition gating and analysis.
For data shown in Figure 1c, 400 000 PBMCs in PBC/2%
FCS were stained with anti-CD3-FITC (HIT3a), CD4-PerCP
(RPA-T4) and CD38-APC (HIT2) (all from BD Biosciences) for
30 min on ice. Cells were washed twice and fixed with 1%
paraformaldehyde (Sigma, Australia), and samples were
acquired on a FACSCalibur (BD Biosciences) using the
CellQuest software. Data were analysed using the Kaluza
software (Beckman Coulter).
Gene expression analysis by qPCR
Cells as detailed in the text were sorted by FACS directly
into RLT buffer and stored at 80°C. On the day of
extraction, frozen cell lysates were thawed quickly on ice
and mRNA was extracted using the RNeasy Micro Kit
(Qiagen) according to the manufacturer’s instructions.
cDNA was synthesised using oligo-dT and Superscript III
(Invitrogen) according to the manufacturer’s instructions.
Gene expression was measured using individual TaqMan
gene expression assays (Applied Biosystems) and Platinum
Taq Polymerase (Life Technologies) in a 15 lL volume
reaction using a Rotor-Gene 3000 PCR machine (Corbett
Research) with the following conditions: 2 min at 50°C for
calibration of fluorescent gain values, then denaturing for
2 min at 95°C, followed by 45 cycles of 5 s at 95°C and 30 s
at 60°C. Gene expression was quantified relative to a
standard curve generated from a titration of cloned cDNA,
and relative gene expression was calculated by dividing the
expression value of the test gene by that of a reference
gene (RPL13A for human studies and b2m for mouse study)
except for the data in Figure 4d, which was normalised as
molecules/cell as the input cell number was accurately
determined beforehand.
T-cell stimulation with Plasmodium antigens
PBMCs (4 9 105) from adult patients with uncomplicated P.
falciparum malaria (Sabah) were co-cultured for 24 h in 96-
well U-bottom plates with RPMI supplemented with 10%
human AB serum and with an extract equivalent to 4 9 105
P. falciparum-parasitised RBCs (pRBCs), or a control extract
made from equivalent numbers of uninfected RBCs (nRBCs).
The pRBC and nRBC extracts were made as described
previously75. Following the incubation period, the cells
were harvested and sorted by flow cytometry into
populations of CD4hiCD38hi or CD4norm T cells. Following
the FACS sort, the cells were resuspended in RLT lysis buffer
and PCR was performed as described above.
mRNA expression using NanoString
Expression of 130 immune-related genes known to be
involved in T-cell and B-cell responses was assessed using a
custom 130-plex nCounter codeset of genes involved in
immune recognition, survival, migration, adhesion,
cytokine/chemokine secretion, activation, differentiation
and exhaustion, as reported previously76. CD4norm and
CD4hiCD38hi T cells were sorted by FACS from PBMCs from
samples as detailed in the text. The sorted cells were
stimulated for 3 h with PMA (5 ng mL1) and ionomycin
(500 ng mL1) in RPMI supplemented with 10% human AB
serum and penicillin–streptomycin–glutamine (PSG).
Following the stimulation, the cells were washed and
resuspended in RLT lysis buffer (2 9 103 cells lL1) and
stored at 70°C until use. nCounter codeset hybridisation
was performed as per the manufacturer’s instructions using
5 lL of cell lysate (104 cells). Samples were processed using
the NanoString GEN2 Prep Station and data acquired using
the nCounter Digital Analyzer (NanoString Technologies).
Data were normalised to the mean RPLP0 expression levels
and processed using nSolver (NanoString Technologies)
using the recommended settings. The limit of detection was
set as the average reading for the negative controls plus 2
SD; all values below this were raised to this value, and all
data were then log2-normalised for statistical analysis.
Genes were considered as reproducibly detected if they
were above the limit of detection in at least 50% of the
samples. Principal component analysis, ANOVA, paired t-
tests, LEfSe and Random Forest analysis were performed
using the Genomics Data Miner21. Heatmaps were
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generated using Heatmapper77, and data were ordered
according to average fold change between CD4norm and
CD4hiCD38hi groups.
PBMC culture with IL-27
PBMCs from healthy Brisbane volunteers were co-cultured
with an extract made from P. falciparum-infected RBC (as
detailed above) at the equivalent of 1xpRBC:1xPBMC in
media alone (RPMI, with 5% human AB serum, PSG and 20
units per mL rIL-2), or further supplemented with IL-27
(100 ng mL1) in 2.5 mL at 2.5 9 106 PBMCs/well in 12-well
tissue culture plates for 8 days; then, the cells were split
into 2 wells of 6-well plates with 5 mL of fresh media and
supplements and cultured for further 6 days (recombinant
IL-2 was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, National Institute of
Allergy and Infectious Diseases and National Institutes of
Health: human rIL-2 from Dr Maurice Gately, Hoffmann-
LaRoche (Nutley, NJ); recombinant IL-27 from BioLegend.
After 13 days of culture, the cells were restimulated for
24 h with the addition of pRBC extract (equivalent of 106
pRBC mL–1); then, the cells were harvested, and 10 9 103
CD4+ T cells were sorted by FACS and immediately
resuspended into 200 lL of RLT lysis buffer and stored at
80°C until processed for qPCR.
Mice
Specific pathogen-free BALB/c and C57BL/6 mice were
purchased from the Animal Resources Centre, Perth, WA,
and were used at 6 or 9 weeks of age. Interferon-gamma
reporter mice were purchased from the Jackson
Laboratories (C.129S4(B6)-Ifngtm3.1Lky/J; stock No. 017580)
and bred at QIMR Berghofer Medical Research Institute. All
studies were approved by the QIMR Berghofer Medical
Research Institute Animal Research Ethics Committee.
Mouse Plasmodium infections
To generate stocks of parasitised RBC (pRBC), BALB/c mice
were infected by tail-vein injection of 1000 cryopreserved
infectious P. yoelii sporozoites (17XNL non-lethal strain)
kindly provided by Dr SL Hoffman (Sanaria Inc., Rockville,
MD, USA) and blood-stage parasitaemia was monitored by
FCAB assay23. On day 14, the mice were euthanised and the
parasitised blood was collected and stored in freezing
buffer in liquid nitogen. Blood-stage infections reported
herein were initiated by tail-vein injection of 105 pRBC, and
the infection was monitored daily by FCAB assay23. For
kinetic analysis of CD4 and IFN-c expression in GREAT IFN-c
reporter mice, GREAT mice were infected with P. yoelii as
described above, and on the days indicated in the text,
three mice were selected randomly for euthanisation, and
organs and blood were collected for analysis. Single-cell
suspensions were prepared and analysed by flow cytometry.
Cytokine measurement in mouse plasma was assessed by
cytokine bead array (BD Biosciences) using 10 lL of plasma
taken from the tail tip of infected mice on the days shown
in the text.
Statistical methods
Statistical analyses in Figures 1, 2, 4 and 5 were performed
using GraphPad Prism 6 (GraphPad Software Inc.). Data in
Figure 1c were analysed using the Kruskal–Wallis test
followed by post-tests comparing each group with HC. Data
in Figures 2, 4 and 5 were log2-normalised and analysed
using a paired t-test. In Figure 3, all data were then log2-
normalised for statistical analysis and principal component
analysis, ANOVA, paired t-tests, LEfSe and Random Forest
analysis were performed using the Genomics Data Miner21.
Heatmaps were generated using Heatmapper77.
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